# PRESS RELEASE BODY Lexington BioVentures has been awarded a $5.1 million grant from the National Institutes of Health to accelerate its equine genomics research program, which aims to establish horses as a premier model for human disease investigation and therapeutic development. The five-year grant, administered through the NIH's Division of Program Coordination, Planning, and Strategic Initiatives, will fund the company's innovative sequencing and phenotypic analysis platform designed to unlock genetic markers associated with complex diseases affecting both equine and human populations. The research initiative focuses on leveraging the horse's unique biological similarities to humans, including comparable cardiovascular, metabolic and musculoskeletal systems. By establishing comprehensive genomic databases and developing predictive models, Lexington BioVentures aims to accelerate drug discovery timelines and reduce preclinical development costs for pharmaceutical companies. "This NIH recognition validates our vision of bridging equine science and human medicine," said Dr. Margaret Chen, Chief Scientific Officer at Lexington BioVentures. "The grant positions us to create a transformative resource that pharmaceutical developers can access to identify promising therapeutic candidates more efficiently than traditional methodologies." The research will be conducted at Lexington BioVentures' advanced genomics facility and through collaborations with leading academic institutions specializing in veterinary and translational medicine. **About Lexington BioVentures** Lexington BioVentures, based in Lexington, Kentucky, is a healthcare innovation company developing advanced genomic research platforms and disease modeling solutions. The company bridges veterinary science and human medicine to accelerate therapeutic discovery and development. For more information, visit lexingtonbioventures.com.